These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30230140)

  • 1. Sera with anti-enteric neuronal antibodies from patients with irritable bowel syndrome promote apoptosis in myenteric neurons of guinea pigs and human SH-Sy5Y cells.
    Fan W; Fei G; Li X; Wang X; Hu C; Xin H; Sun X; Li Y; Wood JD; Fang X
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13457. PubMed ID: 30230140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sera anti-neuronal antibodies in patients with irritable bowel syndrome and their correlations with clinical profiles.
    Fan W; Fang X; Fei G; Li X; Guan H
    Neurogastroenterol Motil; 2023 Nov; 35(11):e14682. PubMed ID: 37743699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility.
    De Giorgio R; Bovara M; Barbara G; Canossa M; Sarnelli G; De Ponti F; Stanghellini V; Tonini M; Cappello S; Pagnotta E; Nobile-Orazio E; Corinaldesi R
    Gastroenterology; 2003 Jul; 125(1):70-9. PubMed ID: 12851872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients.
    Buhner S; Li Q; Berger T; Vignali S; Barbara G; De Giorgio R; Stanghellini V; Schemann M
    Neurogastroenterol Motil; 2012 Dec; 24(12):1134-e572. PubMed ID: 22963673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies in patients with gut motility disorders and enteric neuropathy.
    Törnblom H; Lang B; Clover L; Knowles CH; Vincent A; Lindberg G
    Scand J Gastroenterol; 2007 Nov; 42(11):1289-93. PubMed ID: 17918010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons.
    Balestra B; Vicini R; Cremon C; Zecchi L; Dothel G; Vasina V; De Giorgio R; Paccapelo A; Pastoris O; Stanghellini V; Corinaldesi R; De Ponti F; Tonini M; Barbara G
    Neurogastroenterol Motil; 2012 Dec; 24(12):1118-e570. PubMed ID: 22937879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.
    Pimentel M; Morales W; Rezaie A; Marsh E; Lembo A; Mirocha J; Leffler DA; Marsh Z; Weitsman S; Chua KS; Barlow GM; Bortey E; Forbes W; Yu A; Chang C
    PLoS One; 2015; 10(5):e0126438. PubMed ID: 25970536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-enteric neuronal antibodies and the irritable bowel syndrome.
    Wood JD; Liu S; Drossman DA; Ringel Y; Whitehead WE
    J Neurogastroenterol Motil; 2012 Jan; 18(1):78-85. PubMed ID: 22323991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen.
    Kohr D; Tschernatsch M; Schmitz K; Singh P; Kaps M; Schäfer KH; Diener M; Mathies J; Matz O; Kummer W; Maihöfner C; Fritz T; Birklein F; Blaes F
    Pain; 2009 Jun; 143(3):246-251. PubMed ID: 19375222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of celiac disease and related antibodies in patients diagnosed with irritable bowel syndrome according to the Rome III criteria. A case-control study.
    Sánchez-Vargas LA; Thomas-Dupont P; Torres-Aguilera M; Azamar-Jacome AA; Ramírez-Ceervanes KL; Aedo-Garcés MR; Meixueiro-Daza A; Roesch-Dietlen F; Grube-Pagola P; Vivanco-Cid H; Remes-Troche JM
    Neurogastroenterol Motil; 2016 Jul; 28(7):994-1000. PubMed ID: 26914655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
    Rezaie A; Park SC; Morales W; Marsh E; Lembo A; Kim JH; Weitsman S; Chua KS; Barlow GM; Pimentel M
    Dig Dis Sci; 2017 Jun; 62(6):1480-1485. PubMed ID: 28451914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome.
    Dothel G; Barbaro MR; Boudin H; Vasina V; Cremon C; Gargano L; Bellacosa L; De Giorgio R; Le Berre-Scoul C; Aubert P; Neunlist M; De Ponti F; Stanghellini V; Barbara G
    Gastroenterology; 2015 May; 148(5):1002-1011.e4. PubMed ID: 25655556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome.
    Hod K; Ringel-Kulka T; Martin CF; Maharshak N; Ringel Y
    J Clin Gastroenterol; 2016 Mar; 50(3):227-32. PubMed ID: 25930973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics.
    Bennet SMP; Palsson O; Whitehead WE; Barrow DA; Törnblom H; Öhman L; Simrén M; van Tilburg MAL
    Neurogastroenterol Motil; 2018 Oct; 30(10):e13378. PubMed ID: 29797382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models.
    Xu JR; Luo JY; Shang L; Kong WM
    Chin J Dig Dis; 2006; 7(2):89-96. PubMed ID: 16643336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based case-control study.
    Pittock SJ; Lennon VA; Dege CL; Talley NJ; Locke GR
    Dig Dis Sci; 2011 May; 56(5):1452-9. PubMed ID: 21181442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the Enteric Nervous System to Autoimmune Diseases and Irritable Bowel Syndrome.
    Annaházi A; Schemann M
    Adv Exp Med Biol; 2022; 1383():1-8. PubMed ID: 36587141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence and functional effects of serum antineuronal antibodies in patients with gastrointestinal disorders.
    Lütt A; Michel K; Krüger D; Volz MS; Nassir M; Schulz E; Poralla L; Tangermann P; Bojarski C; Höltje M; Teegen B; Stöcker W; Schemann M; Siegmund B; Prüss H
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13292. PubMed ID: 29345029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.
    Morales W; Rezaie A; Barlow G; Pimentel M
    Dig Dis Sci; 2019 Nov; 64(11):3115-3121. PubMed ID: 31152332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome.
    Hod K; Dickman R; Sperber A; Melamed S; Dekel R; Ron Y; Halpern Z; Berliner S; Maharshak N
    Neurogastroenterol Motil; 2011 Dec; 23(12):1105-10. PubMed ID: 21951717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.